APGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apogee Therapeutics Inc (APGE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive long-term catalysts, and hedge fund buying trends, making it a compelling opportunity despite short-term price fluctuations.
The technical indicators show a mixed but generally positive trend. The MACD is positive and contracting, RSI is neutral at 54.808, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 70.103, with support at 67.013 and resistance at 73.194, indicating a stable price range.
Analysts have reiterated strong Buy ratings with price targets ranging from $83 to $137, citing promising Phase 1b and Phase 2a data for zumilokibart in asthma and atopic dermatitis.
Hedge funds are significantly increasing their positions in APGE, with a 2216.65% increase in buying activity last quarter.
The company has a strong cash reserve of $902.9 million to support ongoing R&D and future developments.
Recent price decline of -1.92% in regular trading and -0.57% in pre-market trading.
RBC Capital downgraded the stock to Sector Perform, citing valuation concerns and a crowded market.
The company reported a net loss of $255.8 million in 2025, reflecting high R&D expenditures.
In Q4 2025, Apogee reported a net income of -$69.39 million, a 3.23% YoY improvement. However, EPS declined by -11.97% YoY to -1.03, reflecting ongoing R&D investments. The company maintains a robust cash reserve of $902.9 million, ensuring financial stability for future developments.
Analysts are overwhelmingly positive on APGE, with multiple Buy ratings and price targets as high as $137. Citi and Wedbush highlight the positive risk/reward profile and potential for Phase 3 trials in 2026. However, Wolfe Research and RBC Capital express caution due to valuation concerns and potential near-term negative catalysts.
